Complement propriety and conspiracy in nanomedicine: Perspective and a hypothesis

Nucleic Acid Therapeutics

Volumn 26, Issue 2, 2016, Pages 67-72

  Moghimi, Seyed Moein ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHYLATOXIN; COMPLEMENT; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; IMMUNOLOGICAL ADJUVANT; IMMUNOLOGIC FACTOR;

ADJUVANT THERAPY; ALTERNATIVE HYPOTHESIS; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; HUMAN; INFUSION RELATED REACTION; NANOMEDICINE; NONHUMAN; OPSONIZATION; PHAGOCYTIC CLEARANCE; PHAGOCYTOSIS AND RELATED PHENOMENA; PRIORITY JOURNAL; ANIMAL; DISEASE MODEL; IMMUNOLOGY; INNATE IMMUNITY; LUNG; PHAGOCYTOSIS; PHYSIOLOGY; PRECLINICAL STUDY; VASCULARIZATION;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; LUNG; NANOMEDICINE; PHAGOCYTOSIS;

EID: 84964452135     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2015.0587     Document Type: Article

References (66)

1. Dunkelberger JR and W-C Song. (2010). Complement and its role in innate and adaptive immune responses. Cell Res 20: 34-50
2. Moghimi SM, AJ Andersen, D Ahmadvand, PP Wibroe, TL Andresen and AC Hunter. (2011). Material properties in complement activation. Adv Drug Deliv Rev 63: 1000-1007
3. Inturi S, G Wang, F Chen, NK Banda, AM Holders, LP Wu, SM Moghimi and D Simberg. (2015). Modulatory role of surface coating of superparamagnetic iron oxide nanoworms in complement opsonization and leukocyte uptake. ACS Nano doi: 10.1021/acsnano.5b05061.
4. Moghimi SM, AC Hunter and TL Andresen. (2012). Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol 52: 481-503
5. Jiang H, B Cooper, FA Robey and H Gewurz. (1992). DNA binds and activates complement via residues 14-26 of the human C1q A chain. J Biol Chem 267: 25597-25601
6. Plank C, K Mechtler, FC Szoka Jr and E Wagner. (1996). Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Human Gene Ther 17: 1437-1446
7. Wu LP, M Ficker, JB Christensen, PN Trophopoulos and SM Moghimi. (2015). Dendrimers in medicine: therapeutic concepts and pharmaceutical challenges. Bioconjug Chem 26: 1198-1211
8. Moghimi SM, I Hamad, TL Andresen, K Jørgensen and J Szebeni. (2006). Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J 20: 2591-2593
9. Andersen AJ, JT Robinson, H Dai, AC Hunter, TL Andresen and SM Moghimi. (2013). Single-walled carbon nanotube surface control of complement recognition and activation. ACS Nano 7: 1108-1119
10. Hamad I, O Al-Hanbali, AC Hunter, KJ Rutt, TL Andresen and SM Moghimi. (2010). Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano 4: 6629-6638
11. Von Zabern, I. (2004). Effects of drugs, venoms and charged polymers on the complement system. 6c. Action of polyionic substances on the complement system. In: Activators and Inhibitors of Complement. Sim RB, ed.. Springer Science+Business Media, Dordrecht, pp 149-166
12. Manegold CD, D Gravenor, D Woytowitz, J Mezger, V Hirsh, G Albert, M Al-Adhami, D Readett, AM Krieg and CG Leichman. (2008). Randomized phase II trial of a tolllike receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3979-3986
13. Schneeberger A, C Wagner, A Zemann, P Lührs, R Kutil, M Goos, G Stingl and SN Wagner. (2004). CpG motifs are efficient adjuvants for DNA cancer vaccines. J Invest Dermatol 123: 371-379
14. Magsbo AM, J Sanchez, K Anger, JD Lambris, KN Ekdahl, AS Loskog, B Nilsson and TH Tötterman. (2009). Complement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effect. J Immunol 183: 6724-6732
15. Zhang X, Y Kimura, C Fang, L Zhou, G Sfyroera, JD Lambris, RA Wetsel, T Miwa and W-C Song. (2007). Regulation of toll-like receptor-mediated inflammatory response by complement in vivo. Blood 110: 228-236
16. Song WC. (2012). Crosstalk between complement and tolllike receptors. Toxicol Pathol 40: 174-182
17. Dempsey PW, ME Allison, S Akkaraju, CC Goodnow and DT Fearon. (1996). C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271: 348-350
18. Bajic G, L Yatime, RB Sim RB, T Vorup-Jensen and GR Andersen. (2013). Structural insight on the recognition of surface-bound opsonins by the integrin I domain of complement receptor 3. Proc Natl Acad Sci U S A 110: 16426-16431
19. Moghimi SM, PP Wibroe, S Helvig, ZS Farhangrazi and AC Hunter. (2012). Genomic perspectives in inter-individual adverse responses following nanomedicine administration: the way forward. Adv Drug Deliv Rev 64: 1385-1393
20. Moghimi SM and ZS Farhangrazi. (2013). Nanomedicine and the complement paradigm. Nanomed Nanotechnol Biol Med 9: 458-460
21. Klos A, AJ Tenner, KO Johswich, RR Ager, ES Reis and J Köhl. (2009). The role of the anaphylatoxins in health and disease. Mol Immunol 46: 2753-2766
22. Guo RF and PA Ward. (2005). Role of C5a in inflammatory responses. Annu Rev Immunol 23: 821-852
23. Rittirsch D, H Redl and M Huber-Lang. (2012). Role of complement in multiorgan failure. Clin Dev Immunol 962927
24. Mrkiewski MM, RA DeAngelis, F Benecia, SK Ricklin- Lichtsteiner, A Koutoulaki, C Gerard, G Coukos and JD Lambris. (2008). Modulation of the antitumor immune responses by complement. Nat Immunol 9: 1225-1235
25. Moghimi SM and ZS Farhangrazi. (2014). Just so stories: the random act of anti-cancer nanomedicine performance. Nanomed Nanotechnol Biol Med 10: 1661-1666
26. Moghimi SM. (2014). Cancer nanomedicine and the complement system activation paradigm: anaphylaxis and tumour growth. J Control Release 190: 556-562
27. Sabnani MK, R Rajan, B Rowland, V Mavinkurve, LM Wood, AA Gabizon and NM La-Beck. (2015). Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses. Nanomed Nanotechnol Biol Med 11: 259-262
28. Szebeni J, F Muggia, A Gabizon and Y Barenholz. (2011). Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 63: 1020-1030
29. Szebeni J. (2014). Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biological. Mol Immunol 61: 163-173
30. Szebeni J, P Bedocs, D Csukás, L Rosivall, R Bünger and R Urbanics. (2012). A porcine model of complementmediated infusion reactions to drug carrier nanosystems and other medicines. Adv Drug Deliv Rev 64: 1706-1716
31. Szebeni J, L Baranyi, S Sávay, M Bodó, J Milosevits, CR Alving and R Bünger. (2006). Complement activationrelated cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am J Physiol Heart Cir Physiol 290: H1050-H1058
32. Szebeni J, JL Fontana, NM Wassef, PD Morgan, DS Morse, De Dobbins, GL Stahl, R Bünger and CR Alving. (1999). Hemodynamic changes induced by liposomes and liposomeencapsulated hemoglobin in pigs: a model of pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 99: 2302-2309
33. Chanan-Khan A, J Szebeni, S Savay, L Liebes, NM Rafique, CR Alving and FM Muggia. (2003). Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 14: 1430-1437
34. Chitko-McKown CG and F Blecha. (1992). Pulmonary intravascular macrophages: a review of immune properties and functions. Ann Recherches Vétérinaires 23: 201-214
35. Warner AE. (1996). Pulmonary intravascular macrophages. Clin Chest Med 17: 125-135
36. Miyamoto K, E Scultz, T Heath, MD Mitchell, KH Albertine and NC Staub. (1988). Pulmonary intravascular macrophages and hemodynamic effects of liposomes in sheep. J Appl Physiol 64: 1143-1152
37. Sone Y, VB Serikov and NC Staub Sr. (1999). Intravascular macrophage depletion attenuates endotoxin lung injury in anesthetized sheep. J Appl Physiol 87: 1354-1359
38. Stone Y, A Nicolaysen and NC Staub Sr. (1997). Effect of particles on sheep lung hemodynamics parallels depletion and recovery of intravascular macrophages. J Appl Physiol 83: 1499-1507
39. Longworth KE, AM Westgate, MK Grady, JY Westcott and NC Staub. (1992). Development of pulmonary intravascular macrophages function in newborn lambs. J Appl Physiol 73: 2608-2615
40. Schneberger D, D Lewis, S Caldwell and B Singh. (2011). Expression of toll-like receptor 9 in lungs of pigs, dogs and cattle. Int J Exp Pathol 92: 1-7
41. Wassef A, K Janardhan, JW Pearce and B Singh. (2004). Toll-like receptor 4 in normal and inflamed lungs and other organs of pig, dog and cattle. Histol Histopathol 19: 1201-1208
42. Kawai T and S Akira. (2011). Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34: 637-650
43. Schneberger D, K Abaronson-Raz and B Singh. (2012). Pulmonary intravascular macrophages and lung health: what are we missing?. Am J Physiol Lung Mol Cell Physiol 302: L498-L503
44. Dehring DJ and BL Wismar. (1989). Intravascular macrophages in pulmonary capillaries of humans. Am Rev Respir Dis 139: 1027-1029
45. Keyes JW Jr, GA Wilson and JD Quinonest. (1973). An evaluation of lung uptake of colloid during liver imaging. J Nucl Med 14: 687-691
46. Imarisio JJ. (1975). Liver scan showing intense lung uptake in neoplasia and infection. J Nucl Med 16: 188-190
47. Lantto T, M Luostarinen and M Vorne. (1986). Clinical significance of lung uptake in liver scanning. Nuklearmedizin 25: 15-18
48. Mit-Noirault E, L Faure, Y Guichard, J Monthrau and A Le Pape. (2001). Scintigraphic in vivo assessment of the development of pulmonary intravascular macrophages in liver disease. Chest 120: 941-947
49. Smith JS, J Tian, JN Lozier and AP Byrnes. (2004). Severe pulmonary pathology after intravenous administration of vectors in cirrhotic rats. Mol Ther 9: 932-941
50. Smith JS, J Tian, J Muller and AP Byrnes. (2004). Unexpected pulmonary uptake of adenoviruses in animals with chronic liver disease. Gene Ther 11: 431-438
51. Gill SS, SS Suri, KS Janardhan, S Caldwell, T Duke and B Singh. (2008). Role of pulmonary intravascular macrophages in endotoxin-induced lung inflammation and mortality in a rat model. Respir Res 9: 69
52. Thenappan T, A Goel, G Marsboom, YH Fang, PY Toth, HJ Zhang, H Kajimoto, Z Hong, J Paul, et al. (2011). A central role for CD68+ macrophages in hepatopulmonary syndrome. Reversal by macrophage depletion. Am J Respir Crit Care Med 183: 1080-1091
53. Marone G, V Patella, G De Crescenzo, A Genovese and M Adt. (1995). Human heart mast cells in anaphylaxis and cardiovascular disease. Int Arch Allergy Immunol 107: 72-75
54. Moghimi SM and J Szebeni. (2003). Stealth liposomes and long-circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42: 463-478
55. Laverman P, MG Carstens, G Storm and SM Moghimi. (2001). Recognition and clearance of methoxypoly (ethyleneglycol)2000-grafted liposomes by macrophages with enhanced phagocytic capacity. Implications in experimental and clinical oncology. Biochim Biophys Acta 1526: 227-229
56. Moghimi SM and T Gray. (1997). A single dose of intravenously injected poloxamine-coated long-circulating particles triggers macrophage clearance of subsequent doses in rats. Clin Sci 93: 371-379
57. Moghimi SM and JC Murray. (1996). Poloxamer-188 revisited: a potentially valuable immune modulator?. J Natl Cancer Inst 88: 766-768
58. Moghimi SM, H Hedeman, NM Christy, L Illum and SS Davis. (1993). Enhanced hepatic clearance of intravenously administered sterically stabilized microspheres in zymosanstimulated rats. J Leukoc Biol 54: 513-517
59. Moghimi SM and AC Hunter. (2001). Capture of stealth nanoparticles by body?s defences. Crit Rev Ther Drug Carrier Syst 18: 527-550
60. Moghimi SM, D Peer and R Langer. (2011). Reshaping the future of nanopharmaceuticals: ad iudicium. ACS Nano 5: 8454-8458
61. Castells M. (2006). Desensitization for drug allergy. Curr Opin Allergy Clin Immunol 6: 476-481
62. Toy R, PM Peiris, KB Ghaghada and E Karathanasis. (2013). Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine (Lond) 9: 121-133
63. Elmen W, W Li and M Kirschfink. (2010). Therapeutic complement inhibition: new developments. Semin Thromb Hemost 36: 660-668
64. Ricklin D and JD Lambris. (2013). Progress and trends in complement therapeutics. Adv Exp Med Biol 735: 1-22
65. Yatime L, C Maasch, K Hoehlig, S Klussmann, GR Andersen and A Vater. (2015). Structural basis for the targeting of complement anaphylatoxin C5a using a mixed L-RNA/L-DNA aptamer. Nat Commun 6: 6481
66. Pellas TC and LP Wennogle. (1999). C5a receptor antagonists. Curr Pharm Des 5: 737-755